Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Cerilliant
Chinese Patent Office
Dow
Boehringer Ingelheim
QuintilesIMS
Julphar
Mallinckrodt

Generated: December 9, 2018

DrugPatentWatch Database Preview

ZEJULA Drug Profile

« Back to Dashboard

When do Zejula patents expire, and when can generic versions of Zejula launch?

Zejula is a drug marketed by Tesaro Inc and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-eight patent family members in forty countries.

The generic ingredient in ZEJULA is niraparib tosylate. One supplier is listed for this compound. Additional details are available on the niraparib tosylate profile page.

Summary for ZEJULA
Drug patent expirations by year for ZEJULA
Generic Entry Opportunity Date for ZEJULA
Generic Entry Date for ZEJULA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZEJULA
Synonyms for ZEJULA
(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
0919AA
1038915-60-4
1038915-60-4 pound notMK4827 pound not MK 4827
2-[4-[(3S)-3-Piperidyl]phenyl]indazole-7-carboxamide
2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide
2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-
A3617
AC-28447
AJ-108285
AK102507
AKOS016004869
ANW-62065
AX8234046
BCP0726000077
BCP9000940
BDBM50316226
CHEMBL1094636
compound 56 [PMID 19873981]
CS-0780
CTK8B9123
D00BMF
D10140
DB-059068
DB11793
DTXSID50146129
EX-A290
FT-0770704
GTPL8275
HE242983
HMC2H89N35
HY-10619
KB-03718
MK 4827
MK 4827 (Base)
MK-4827
MK-4827,(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxaMide
MK-4827(Niraparib)
MK-4827/MK4827
MK4827
MolPort-023-219-142
NCGC00346435-01
Niraparib
Niraparib (USAN)
Niraparib [USAN:INN]
Niraparib HCl
Niraparib hydrochloride
s2741
SCHEMBL1421875
TC-150810
UNII-HMC2H89N35
W-5696
Zejula (TN)
ZINC43206370

US Patents and Regulatory Information for ZEJULA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tesaro Inc ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Tesaro Inc ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Tesaro Inc ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Argus Health
Dow
Daiichi Sankyo
Express Scripts
Cerilliant
Colorcon
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.